Chinese Biotechs Raise $743m In Three March IPOs
Executive Summary
RemeGen touched down in Shanghai to score a dual listing on top of a 2020 initial public offering in Hong Kong. Meanwhile, domestic HPV vaccine maker Recbio and small molecule-focused Shouyao made their debuts on the Hong Kong and Shanghai markets respectively.
You may also be interested in...
China’s First ADC Secures Domestic Approval
RemeGen’s second approval after a green light for its lupus drug signals accelerating approvals for domestically-developed antibodies in China.
Chinese Newcomers Look For Niche Immuno-Oncology Opportunities
Chinese pharma companies are continuing to pile into the already overcrowded domestic anti-PD-1/L1 sector in China, but despite the competition and regulatory tightening, the latecomers are looking for opportunities in areas such as cervical and small cell lung cancer with relatively fewer contenders.
Sino Biopharm Completes F-Star Acquisition After US CFIUS Review
Sino Biopharm's $161m all-cash acquisition of F-star has finally closed amid heightening US-China tensions and following completion the Chinese firm, through its UK subsidiary invoX, plans to expand its operations and presence at F-star’s UK headquarters.